Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says

  • RBC Capital Markets initiated coverage on Bio-Rad Laboratories Inc BIO with an Outperform rating and a $565 price target.
  • The analyst writes that Bio-Rad has evolved as a public company over the last eight years. 
  • Many investors have probably overlooked the new Bio-Rad with new management, financial metrics more in line with peers, and a refreshed product portfolio. 
  • BIO's ddPCR product line, launched in 2020, gives Bio-Rad access to the $2 billion biopharma production total addressable market where they haven't historically been present. 
  • Additional ddPCR product launches scheduled for 2022 and 2023 will expand the addressable market.
  • Also see: Bio-Rad Laboratories, Qiagen Mull Merger Of Equals.
  • Further, the analyst writes that investors are not giving appropriate credit for the value of the company's 35% stake in the public bioproduction company Sartorius.
  • After lagging peers by ~300 bps before 2017, the company is now around 300 bps ahead of its competitors, targeting a 9% organic revenue CAGR from 2021-2025.
  • RBC analyst also notes that at 7.3x FY'23 EBITDA and 1.7x FY'23 revenue estimates, BIO trades at a 60-70% discount to peers.
  • Price Action: BIO shares are up 0.58% at $401.90 on the last check Wednesday.
Price Target
Posted In: Analyst ColorNewsHealth CareInitiationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!